Search Results

You are looking at 1 - 2 of 2 items for

  • Author or Editor: Crystal D. Hariu x
  • Refine by Access: All Content x
Clear All Modify Search

A 5-year-old 28.9-kg (63.6-lb) neutered male Boxer was referred to the Veterinary Medical Teaching Hospital at Texas A&M University for evaluation of an arrhythmia that was ausculted during routine physical examination. Two episodes of syncope had occurred 2 days prior to the evaluation. Additionally, occasional instances of cough were reported. The dog was successfully treated for heartworm infection 4 years earlier and had been given monthly heartworm preventative regularly since that time. The owner reported that the dog had a history of extreme anxiety during each visit to a veterinary hospital.

At the evaluation, the dog was bright and alert.

Restricted access
in Journal of the American Veterinary Medical Association

Abstract

Objective—To determine the effect of PO administration of pimobendan on clinical and echocardiographic variables and survival time in cats with heart failure characterized by ventricular systolic dysfunction.

Design—Retrospective cohort study.

Animals—27 client-owned cats (16 male and 11 female) with heart failure, treated with pimobendan (mean ± SD dosage, 0.26 ± 0.08 mg/kg [0.118 ± 0.036 mg/lb], PO, q 12 h).

Procedures—Information on medical history, laboratory results, diagnostic imaging findings, treatments received, and survival time were obtained from medical records of cats that received pimobendan because of cardiac disease. When possible, additional follow-up information was obtained through telephone interviews with referring veterinarians and owners.

Results—The mean ± SD age of all 27 cats was 8.9 ± 5.2 years. All cats had received several cardiac medications. Types of heart disease represented included unclassified cardiomyopathy (CM; n = 11 [41%]), dilated CM (8 [30%]), arrhythmogenic right ventricular CM (4 [15%]), congenital heart disease (3 [11 %]), and hypertrophic CM with regional hypokinesis (1 [4%]). All cats had ventricular systolic dysfunction. One cat with systolic anterior motion of the mitral valve became severely hypotensive after initial administration of pimobendan and was excluded from the survival analysis. Median survival time was 167 days (95% confidence interval, 32 to 339 days).

Conclusions and Clinical Relevance—Pimobendan appeared to be well tolerated in cats with heart failure characterized by ventricular systolic dysfunction of various etiologies. Cats with systolic anterior motion of the mitral valve may develop systemic hypotension when treated with pimobendan. Additional studies are needed to establish dosages for pimobendan and its effects before it can be recommended for treatment of cats with CHF.

Restricted access
in Journal of the American Veterinary Medical Association